Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Lawrie, Theresa A ^a   Bryant, Andrew ^b   Cameron, Alison ^c   Gray, Emma ^d   Morrison, Jo ^d  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^d MUSGROVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; EPOTHILONE B; GEMCITABINE; PACLITAXEL; PLATINUM; TOPOTECAN; TRABECTEDIN; VINTAFOLIDE; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE; DRUG DERIVATIVE;

ABDOMINAL PAIN; ALLERGIC REACTION; ALLERGY; ALOPECIA; ANEMIA; ARTHRALGIA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; DATA ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MUCOSA INFLAMMATION; MYALGIA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STOMATITIS; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; META ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; NEOPLASM; OVARY TUMOR; TUMOR RECURRENCE;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891701459     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006910.pub2     Document Type: Review

References (152)

1. Rose P, Edwards R, Finkler N, Seiden M, Duska L, Krasner C, et al. Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol. 25, 18S (June 20 Supplement), 2007: LBA5529.
2. Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, et al. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. International Journal of Gynecological Cancer 2010;20(5):772-80.
3. Vergote I, et al. Phase 3 study of canfosfamide (TLK 286) plus pegylated liposomal doxorubicin (PLD) vs PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer. Journal of Clinical Oncology; 2009 ASCO annual meeting. 2009; Vol. 27(15S): abstr 5552.
4. Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Maenpaa J, et al. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer 2012;106(4):633-7.
5. Alexandre J, Brown C, Priou F, De Rauglaudre G, Pfisterer J, Maenpaa J, et al. Should CA 125 still be part of tumour evaluation criteria in ovarian cancer trials? Experience of the GCIG calypso trial. Annals of Oncology, 35th ESMO Congress, Milan, Italy. 2010; Vol. 21(suppl 8):viii 307: abstr. 981P.
6. Baumann KH, Pujade-Lauraine E, Jackisch C, Lubbe D, du Bois A, Brown C, et al. Therapy expectations of patients with recurrent platinum-sensitive ovarian cancer-a German substudy of the calypso/ago-ovar 2.9 trial. International Journal of Gynecological Cancer, 17th International Meeting of ESGO. 2011.
7. Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, et al. Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Annals of Oncology 2012;23(8):2020-7.
8. Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of Oncology 2012;23(5):1185-9.
9. Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecologic Oncology 2011;122(2):226-32.
10. Kurtz J, Hilpert F, Dorum A, Veillard A, Elit L, Buck M, et al. Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial. Journal of Clinical Oncology. 2010 ASCO Annual Meeting, 2010; Vol. 28:15s, (suppl; abstr 5031).
11. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, et al. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Annals of Oncology 2011;22(11):2417-23.
12. Lee CK. Ovar 2.9: A Phase III study compare PLD-doxorubicine-carboplatin (CD) with carboplatin-paclitaxel (CP) in recurrent platin-sensible ovarian cancer. A GCIG study. Archives of Gynecology and Obstetrics, Proceedings of the 58th Congress of the German Society for Gynecology and Obstetrics (DGGG). 2011.
13. Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, et al. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. Journal of the National Cancer Institute 2011;103(17):1338-42.
14. Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, et al. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer 2011;105(3):360-5.
15. Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, et al. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer 2011;105(8):1144-50.
16. Mahner S, Meier W, Du Bois A, Brown C, Lorusso D, Ferrero A, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial. Journal of Clinical Oncology. 2011 ASCO Annual Meeting, 2011; Vol. 29 (suppl; abstr 5059).
17. Marth C, Alexandre J, Hanker LC, Brown C, Kaern J, Heywood M, et al. Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. Journal of Clinical Oncology. 2011 ASCO Annual Meeting, 2011; Vol. 29: (suppl; abstr 5052).
18. Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). Journal of Clinical Oncology. 2009 ASCO Annual Meeting, 2009; Vol. 27:18s (suppl; abstr LBA5509).
19. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Journal of Clinical Oncology 2010;28(20):3323-9.
20. Simes R, Lee CK, Mirza M, Sauthier P, Georgopoulos A, Vergote I, et al. The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer. Results from the calypso study. Asia-Pacific Journal of Clinical Oncology, 37th Annual Meeting of the Clinical Oncological Society of Australia (COSA). 2010; Vol. 6 (Suppl 3):150-253: Abstr. 262.
21. Vasey P. A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients. European Journal of Cancer, Joint 15th ECCO-34th ESMO Multidiciplinary Congress, Berlin, Germany. 2009.
22. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. British Journal of Cancer 2012;107(4):588-91.
23. Åvall-Lundqvist E, Wimberger P, Gladieff L, Gebski V, Huober JB, Floquet A, et al. Pegylated liposomal doxorubicin (PLD)-carboplatin (C) (C-D) vs paclitaxel-carboplatin (C-P) in relapsing sensitive ovarian cancer (OC): A 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study. Journal of Clinical Oncology. 2008 ASCO Annual Meeting, 2008; Vol. 26 (May 20 suppl; abstr 5565).
24. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, et al. Randomized, open-Label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology 2012;30(31):3841-7.
25. Capri S, Cattaneo G. Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. Clinical therapeutics 2003;25(6):1826-45.
26. Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. The Oncologist 2007;12(1):72-8.
27. Gordon A. Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer [abstract]. European Journal of Cancer; ECCO Conference. 2003; Vol. 1(5):S51.
28. Gordon A, Sun S, Rackoff W. Incidence of adverse events in women (65 years) with recurrent ovarian cancer receiving pegylated liposomal doxorubicin or topotecan [abstract]. Gynecologic Oncology. 2006; Vol. 101 (1 suppl 1):S59:60.
29. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Journal of Clinical Oncology 2001;19(14):3312-22.
30. Gordon AN, Tonda M, Sun S, Rackoff W, on behalf of the Doxil Study 30-49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecologic Oncology 2004;95(1):1-8.
31. Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou G, Bamias A, Fountzilas G, et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Medicine 2010;8:3:Accessed on 9/11/2012 at http://www.biomedcentral.com/1741-7015/8/3.
32. Kaye S, Kaufman B, Lubinski J, Matulonis U, Gourley C, Karlan B, et al. Phase II study of the oral parp inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations. Annals of Oncology; Proceedings of the 35th ESMO Congress. NCT00628251, 2010; Vol. 21(suppl 8, abstr 9710):viii 304.
33. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology 2012;30(4):372-9.
34. Vergote IB, Colombo N, Kutarska E, Del Campo J, Pippitt C, Casado A, et al. Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. Journal of Clinical Oncology. 2009; Vol. 27:15s, (suppl; abstr 5560).
35. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Journal of Clinical Oncology 2008;26(6):890-6.
36. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology 2007;25(19):2811-8.
37. Mutch DG, Orlando M, Goss T, Wang Y, Lilly E, Teneriello MG, et al. Randomized phase III trial of gemcitabine versus pegylated liposomal doxorubicin for patients with platinum-resistent taxane-pretreated ovarian cancer as second or third line therapy [abstract]. Gynecologic Oncology. 2006; Vol. 101:S14 (1 Suppl 1):5.
38. O'Byrne KJ, Bliss P, Graham JD, Gerber J, Vasey PA, Khanna S, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proceedings of the American Society of Clinical Oncologists. 2002; Vol. 21:808.
39. Bidzinski M, Poveda A, et al. Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer. European Journal of cancer, Supplement, Proceedings of the Joint 15th ECCO - 34th ESMO Multidisciplinary Congress, Berlin. 2009:var. pagings.
40. Boman K, Colombo N. Tolerability of trabectedin (TR) plus pegylated liposomal doxorubicin (PLD) in platinum sensitive (p-s) vs. platinum resistant (P-R) patients (PTS) with relapsed ovarian cancer. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010:var. pagings.
41. Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, et al. Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Annals of Oncology 2012;23(8):2020-7.
42. Colombo N. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study. International Journal of Gynecological Cancer 2011;21(Suppl 1):S12-6.
43. Diebolder H, Runnebaum I. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Yondelis) plus pegylated liposomal doxorubicin (Caelyx [PLD]) combination versus PLD alone: Results from a PPS cohort of the OVA-301 phase III study. Archives of Gynecology and Obstetrics; 58th Congress of the German Society for Gynaecology and Obstetrics (DGGG). 2010.
44. Gore M, Vergote I, Vasanthan S, Chan S, Arranz JA, Colombo N, et al. Cost-effectiveness of trabectedin in combination with pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: Analysis based on the final survival data. European Journal of Cancer; 2011 ECCO Multidisciplinary Cancer Congress, Stockholm, Sweden. 2011; Vol. var. pagings.
45. Herzog TJ, Vermorken JB, Pujade-Lauraine E, Li J, Bayever E, et al. Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone [abstract]. Journal fo Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15s (suppl; abstr 5550).
46. Herzog TJ, Vermorken JB, Pujade-Lauraine E, Provencher DM, Jagiello-Gruszfeld A, Kong B, et al. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. Gynecologic Oncology 2011;122(2):350-5.
47. Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Annals of Oncology 2011;22(1):49-58.
48. Kong B, Biakhov M, Kelley JL, Nunez J, Lebedinsky C, Parekh TV, et al. Influence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone [abstract]. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:7s (supple; abstr e15529).
49. Krasner CN, Poveda A, Herzog T, Vermorken J, Monk B, Zintl P, et al. Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin witj pegylated doxorubicin (PLD) versus PLD alone [abstract]. Journal fo Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15s (suppl; abstr 5526).
50. Krasner CN, Poveda A, Herzog TJ, Vermorken JB, Kaye SB, Nieto A, et al. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecologic Oncology 2012;127(1):161-7.
51. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum, A, et al. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Annals of Oncology 2011;22(11):2417-23.
52. Meerpohl H. Tolerability of long-term use of trabectedin in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). Archives of Gynecology and Obstetrics; 58th Congress of the German Society for Gynaecology and Obstetrics (DGGG). 2010.
53. Monk BJ. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Annals of Oncology; Joint ECCO 15- 34th ESMO Congress. 2009.
54. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia F, et al. Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer [abstract]. Journal of Clinical Oncology; 2011 ASCO Annual Meeting 2011;29:(suppl; abstr 5046).
55. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. Journal of Clinical Oncology 2010;28(19):3107-14.
56. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis. European Journal of Cancer 2012;48(15):2361-8.
57. Poveda A, Kaye SB, McCormack RT, Wang S, Ricci D, Broderick E, et al. Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD. Journal of Clinical Oncology, 2009 ASCO Annual Meeting. 2009; Vol. 27:15s (suppl; abstr 5551).
58. Poveda A, Monk BJ, Kaye SB, Vermorken JB, Nieto A, Gomez J, et al. Prediction of overall survival (OS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): results from OVA-301. European Journal of cancer, Supplement, Proceedings of the 2011 ECCO Multidisciplinary Congress, Berlin. 2011:Abstr:E16-0428.
59. Poveda A, Monk BJ, Kaye SB, Vermorken JB, Vergote IB, Runnebaum IB, et al. Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301. Journal of Clinical Oncology, 2011 ASCO Annual Meeting. 2011; Vol. 29:(suppl; abstr 5067).
60. Poveda A, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, et al. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: results from a PPS cohort of a phase III study [abstract]. Journal of Clinical Oncology, 2010 ASCO Annual Meeting. 2010; Vol. 28:15s, (suppl; abstr 5012).
61. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Annals of Oncology 2011;22(1):39-48.
62. Romero I, Colombo N, Kaye SB, Arranz J, Roszak A, Provencher DM, et al. Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:15s, 2010 (suppl; abstr 5121).
63. Runnebaum IB. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr + PLD) versus PLD alone: Results from a PPS cohort of a phase III study. Archives of Gynecology and Obstetrics; 58th Congress of the German Society for Gynaecology and Obstetrics (DGGG). 2010.
64. Vergote Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older. European Journal of cancer, Supplement, Proceedings of the Joint 15th ECCO - 34th ESMO Multidisciplinary Congress, Berlin. 2009:var pagings.
65. Vergote I, Bidzinski M, Kelley J, Vasanthan S, Runnebaum I, Vermorken J, et al. Health-Related Quality of Life (HRQoL) / Patient Reported Outcomes (PRO) of patients with partially platinum sensitive (PPS) recurrent ovarian cancer (ROC) treated in a randomized phase III trial of trabectedin and PLD vs PLD alone (OVA-301): An Exploratory Analysis. European Journal of Cancer, Supplement, Proceedings of the 2011 ECCO Multidisciplinary Congress, Berlin. 2011:abstr: 8.029.
66. Naumann RW, Coleman RL, Burger RA, Herzog TJ, Morris R, Sausville E, et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. Journal of Clinical Oncology. 2011; Vol. 29: (suppl; abstr 5045).
67. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghaman de SA, et al. PRECENDET: A randomised phase II trial comparing EC145 (Vintafolide) and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in patients with platinum-resistant ovarian cancer. Unpublished manuscript (submitted to the Journal of Clinical Oncology) 2013 (In press).
68. Naumann RW, Symanowski J, Kutarska E, Sharad G, Nashat G, De Pasquale S, et al. EC20 imaging predicts response in a randomized trial comparing pegylated liposomal doxorubicin (PLD) +/- EC145 in platinum-resistant ovarian cancer. International Journal of Gynaecological Cancer, Proceedings of the 17th International Meeting of ESGO. 2011; Vol. 21(suppl 3).
69. Naumann RW, Symanowski JT, Ghamande SA, Gabrail NY, Gilbert MG, Teneriello G, et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer [abstract]. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings. 2010; Vol. 28:18S, (suppl; abstr LBA5012b).
70. Alberts DS, Liu PY, Wilczynski S, Clouser M, Lopez A, Lange M, et al. Phase III randomized trial of pegylated liposomal doxorubicin plus carboplatin versus carboplatin in platinum-sensitive patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group Protocol S0200 [Abstract]. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1. 2007; Vol. 25 (18S).
71. Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecologic Oncology 2008;108(1):90-4.
72. Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecologic Oncology 2010;116(3):323-325.
73. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, et al. Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin or topotecan in 3rd-line treatment of platinum refractory or resistant ovarian cancer: phase III study results [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S (Suppl, abstr. LBA5528).
74. Vergote, I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. European Journal of Cancer 2009;45(13):2324-32.
75. Cherchi PL, Capobianco G, Fattorini F, Canetto AM, Milia L, Cosso M, et al. Second-line therapy with topotecan and pegylated liposomal doxorubicin vs. topotecan slone in patients with recurrent ovarian cancer. International Journal of Gynecological Cancer. 2003 IGCS Annual Meeting, 2003; Vol. 13(Suppl):53.
76. Bookman MA. Erratum. Journal of Clinical Oncology 2009;27(13):2305.
77. Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. [Abstract]. Journal of Clinical Oncology. 2006; Vol. 24 (Suppl 18): A-5002, 256s.
78. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology 2009;27(9):1419-25.
79. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. International Journal of Gynecological Cancer 2003;13(6):735-40.
80. Bookman MA, Gynecologic Cancer InterGroup (GCIG). GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Supplement):5002.
81. Copeland LJB, Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecologic Oncology 2003;90(2 Part 2):S1-7.
82. Kavanagh JJ, Garcia A, Choi H, Gershenson DM, Lewis L, Mascavage J, et al. Efficacy of TLK286 (Telcyta) alone and Inparaplatin® or Doxil® (Caelyx®) in platinum resistant ovarian cancer - results from 3 phase 2 studies [abstract]. International Journal of Gynaecological Cancer. 2004; Vol. 14 (suppl 1):abstr 95:28.
83. Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. Journal of Clinical Oncology 2011;29(27):3628-35.
84. Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, et al. Safety of a 3-weekly schedule of carboplatin plus pegylatedliposomal doxorubicin as first line chemotherapy in patients withovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer 2006;6:202:This article is available from: http://www.biomedcentral.com/1471-2407/6/202.
85. Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology 2009;76(1):49-54.
86. Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Vernaglia Lombardi A, et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO-2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual meeting. 2007; Vol. 25:18S (abstr. 5532).
87. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Ferrandina G, et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO-2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S (suppl; abstr LBA5508).
88. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Legge F, et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (suppl; abstr LBA5033).
89. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Legge F, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: The mito-2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010; Vol. var. pagings.
90. Pignata S, Scambia G, Savarese A, Zagonel V, Gebbia V, Scollo P, et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO-2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, Abstr. 5014).
91. Palaia I, Angioli R, Calcagno M, Zullo MA, Plotti F, Basile S, et al. Liposome-encapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecologic malignancies. International Journal of Gynecological Cancer. 2006; Vol. 16(S3): 799.
92. Scarfone, G, Presti M, Scarabelli C, Polverino GP, Polonio N, Bertoglio S, et al. Pegylated liposomal doxorubicin alone or in combination with platinum compounds in recurrent ovarian cancer after first line chemotherapy containing paclitaxel and carboplatin. International Journal of Gynecological Cancer. 2006; Vol. 16(S3):668.
93. Abbott A trial of ABT-888 in combination with temozolomide versus pegylated liposomal doxorubicin alone in ovarian cancer [Ongoing]. Accessed on 12/11/12 at http://www.http://clinicaltrials.gov/show/NCT01113957.
94. Lai C-H. Phase III randomised trial of maintenance pegylated liposomal doxorubicin/carboplatin versus without in patients with advanced ovarian cancer [Ongoing]. Australia and New Zealand Clinical Trials Registry; 2010; Vol. ACTRN12607000329460:Accessed on 20/11/12 at http://www.anzctr.org.au/ACTRN12607000329460.aspx.
95. Kuhn K. A Crossover bioequivalence study of intravenously administered ATI0918 and DOXIL/CAELYX in patients with ovarian cancer. Accessed on 14/11/12 at ttp://www.clinicaltrials.gov/ct2/show/record/NCT01715168.
96. Hoffmann-La Roche. AURELIA: A study of Avastin (Bevacizumab) added to chemotherapy in patients with platinum-resistant ovarian cancer. Accessed on 14/11/12 at http://www.clinicaltrials.gov/ct2/show/NCT00976911.
97. Meier W, Lichtenegger W, Marth C, Gonzalez-Martin AJ, Harter P, Tome O, et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planed 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR). Journal of Clinical Oncology, 2010 ASCO Annual Meeting. 2010; Vol. 28:15s, (suppl; abstr 5071).
98. Sehouli J, Meier W, Wimberger P, Chekerov R, Belau A, Mahner S, et al. Topotecan plus carboplatin vesus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): a randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR) [abstract]. Journal of Clinical Oncology, 2012 ASCO Annual Meeting. 2012; Vol. 30 (suppl, abstr 5031).
99. ImClone A study of liposomal doxorubicin with or without IMC-3G3 in platinum-refractory or resistant advanced ovarian cancer. Accessed on 14/11/12 at http://www.clinicaltrials.gov/ct2/show/NCT00913835.
100. McGuire WP, Shah GD, Loizos N, Youssoufian H, Rowinsky EK, Gore ME, et al. Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory/resistant advanced ovarian cancer. Journal of Clinical Oncology. 2010; Vol. 28:15s, (suppl; abstr TPS256).
101. Colombo N. INOVATYON STUDY -International, randomized study in patients with ovarian cancer. Accessed on 14/11/12 at http://www.clinicaltrials.gov/ct2/show/NCT01379989.
102. NCT00657878 Liposomal doxorubicin versus carboplatin/paclitaxel in patients with ovarian cancer recurrence between 6 and 12 months after previous platinum based therapy: Phase III randomized multicenter study [Ongoing]. Accessed 13/11/12 at http://clinicaltrials.gov/ct2/show/study/NCT00657878.
103. Zeimet A. Randomized phase II AGO-study comparing combined liposomal doxorubicin (Myocet) and gemcitabine (Gemzar) with liposomal doxorubicin (Myocet) monotherapy in platinum-refractory and platinum-resistant epithelial cancer of the ovary, fallopian tube and the peritoneum. Accessed on 14/11/12 at http://www.clinicaltrials.gov/ct2/show/NCT01100372.
104. Monk B. VTX-2337 and pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Accessed on 14/11/12 at http://clinicaltrials.gov/ct2/show/record/NCT01666444.
105. MolMed Phase II study of NGR-hTNF in combination with doxorubicin in platinum-resistant ovarian cancer (NGR018). Accessed on 14/11/12 at http://clinicaltrials.gov/show/NCT01358071.
106. Endocyte Study for women with platinum resistant ovarian cancer evaluating EC145 in combination with doxil. Accessed on 14/11/12 at http://www.clinicaltrials.gov/ct2/show/NCT01170650.
107. Sehouli J. PROVE A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer. Accessed on 14/11/12 at http://clinicaltrials.gov/ct2/show/NCT01388621.
108. Medpace Recruitment Center. A randomized, controlled, open-label, phase 2 trial of SGI-110 and carboplatin in subjects with platinum-resistant recurrent ovarian cancer. accessed on 14/11/12 at http://www.clinicaltrials.gov/ct2/show/NCT01696032.
109. AMGEN Trial IN OVArian cancer-2. Accessed on 14/11/12 at http://www.clinicaltrials.gov/ct2/show/NCT01281254.
110. Boehringer Ingelheim Pharmaceuticals. Phase II randomized trial of the polo-like kinase 1 inhibitor BI 6727 (Volasertib) monotherapy versus investigatoŕs choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotoxic therapy [Ongoing]. Accessed on 12/11/12 at http://clinicaltrials.gov/ct2/show/NCT01121406.
111. Janssen-Cilag Pty, Ltd CAELYX Product Information. http://www.janssen.com.au/Products/Caelyx Amended 4 January 2011:(Accessed 24 January 2013).
112. CTCAE Common Terminology Criteria for Adverse Events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf) 9th August 2006; Vol. v3.0 (CTCAE).
113. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining for heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith g, Altman DG editor(s). Systematic Reviews in Healthcare: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
114. Dersimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
115. Janssen Products. Important update regarding the availability of DOXIL. http://www.doxil.com/sites/default/files/DOXIL_DHCP_letter_July2011.pdf 2011:(Accessed 24/1/13).
116. European Medicines Agency. EPARs for authorised medicinal products for human use EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000089/WC500020173.pdf 2010; Vol. accessed 24 January 2013.
117. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. on behalf of the ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010;21(suppl 5):v23-30.
118. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003;14 (Supplement 5):v61-v118.
119. Podlekareva Farr K, Safwat A. Palmar-plantar erythodysesthesia associated with chemotherapy and its treatment. Case Reports in Oncology 2011;4:229-35.
120. Ferlay J. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer 2013;49(6):1374-403.
121. FIGO Committee in Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics 2009;105:3-4.
122. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clinical Cancer Research 2001;7(2):223-5.
123. Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of Oncology 2012;23(5):1185-9.
124. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [Internet]. Lyon, France, 2010; Vol. International Agency for Research on Cancer:http://globocan.iarc.fr.
125. Hennessy BT, Coleman RL, Markman M. Ovarian Cancer. Lancet 2009;374:1371-82.
126. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60.
127. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
128. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecologic Oncology 2012;127(1):75-82.
129. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
130. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.
131. Jemel A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer Journal 2011;61(2):69-90.
132. Kavanagh JJ, Levenbach CF, Ramires PT, Wolf JL, Moore CL, Jones MR, et al. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. Journal of Hematology & Oncology; www.jhoonline.org/content/3/1/9 2010;3:9.
133. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erthrodysesthesia ('hand-foot syndrome'). Annals of Oncology 2007;18(7):1159-64.
134. Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E. Prevention strategies in palmar-plantar erythodysesthesia onset: the role of regional cooling. Gynecologic Oncology 2008;108:332-5.
135. Markman M. Serious ethical dilemma of single-agent peylyated liposomal doxorubin employed as a control arm in ovarian cancer chemotherapy trials. Journal of Clinical Oncology 2010;28(19):e319-20.
136. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. Journal of Clinical Oncology 2010;28(19):3107-14.
137. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis. European Journal of Cancer 2012;48(15):2361-8.
138. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011;71:1397-412.
139. National Institute for Clinical Excellence. Guidance on the use of paclitaxel in the treatment of ovarian cancer. NICE: Technology Appraisal Guidance- No. 55 2003.
140. National Institute for Health and Clinical Excellence. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review). www.nice.org.uk/nicemedia/live/11554/33026/33026.pdf 2005:1-4.
141. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
142. Pfisterer J, Lederman JA. Management of platinum-sensitive recurrent ovarian cancer. Seminars in Oncology 2006;33(2 Suppl 6):S12-6.
143. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Annals of Oncology 2011;22(1):39-48.
144. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
145. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005;10:205-14.
146. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Annals of Oncology 1996;7:361-4.
147. Kosary CL. Chapter 16: Cancer of the ovary. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J editor(s). Cancer Survival Among Adults: US SEER Program, 1988-2001. Bethesda: US Department of Health and Human Services; National Cancer Institute, 2007:133-144.
148. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines. Cancer 2004;100(10):2052-63.
149. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000;92:205-16.
150. von Moos R, Thuerlimann BJK, Aapro M, Rayson D, Harrold K, Sehouli J, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. European Journal of Cancer 2008;44:781-90.
151. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. British Journal of Cancer 2012;107(4):588-91.
152. Zunino F, Pratesi G. Antitumour Antibodies. In: Souhami RL, Tannock I, Hohenberger P, Horiot J-C editor(s). Oxford Textbook of Oncology. 2nd Edition. Oxford: Oxford University Press, 2002:715-27.